PTHS — Pelthos Therapeutics Inc.
—
NYSE ·
Health Care ·
Biotechnology ·
CIK 1919246 ·
Last close
$26.50
Market Cap
$92.10M
52W High
$29.64
52W Low
$19.98
ADV30
21,368
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 10,906,000 | 5,594,000 | -13,088,000 | -10,238,000 | 145,378,000 | 31,976,000 | 110,276,000 |
| Dec 2025 | 9,389,000 | 6,126,000 | -12,003,000 | -21,664,000 | 130,397,000 | 17,973,000 | 91,516,000 |
| Sep 2025 | 7,406,000 | 3,845,000 | -15,362,000 | -16,238,000 | 126,433,000 | 14,203,000 | 68,180,000 |
| Jun 2025 | 0 | — | -3,230,423 | -3,448,939 | 822,850 | 59,172 | 7,317,145 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-35,084,000
Investing CF
$-194,000
Financing CF
$72,609,000
CapEx
$-194,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-20.64
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-75,032,000
Inventory
$23,418,000
Receivables
$11,700,000
ST Investments
—
EBIT TTM
$-53,744,423
Pretax Income TTM
$-58,975,939
Interest Exp TTM
$5,231,516
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$27,701,000
EBITDA
—
Free Cash Flow
$-34,339,868
Enterprise Value
$113,059,592
Total Cash
$31,976,000
Total Debt
$52,931,000
Shares Out
3,475,645
Trailing EPS
$-22.92
Book Value
$10.42
ROE
-333.8%
ROA
-36.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 16,795,000 | -32,430,000 | -43,319,000 | 130,397,000 | 91,516,000 | — | -22,590,000 |
| Dec 2024 | 0 | -7,571,000 | -7,955,000 | 1,369,000 | 4,083,000 | — | -5,792,000 |
| Dec 2023 | 0 | -6,862,284 | -7,380,793 | 96,391 | 6,540,943 | — | -981,031 |
| Dec 2022 | 0 | -2,318,159 | -2,458,589 | 55,074 | 3,761,611 | — | -1,567,149 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.12
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | $89.74M | $9.96 | — |
| CSBR | CHAMPIONS ONCOLOGY, INC. | $88.04M | $6.34 | — |
| CRDF | Cardiff Oncology, Inc. | $97.09M | $1.42 | — |
| BDTX | Black Diamond Therapeutics, Inc. | $98.56M | $1.72 | — |
| KLRS | Kalaris Therapeutics, Inc. | $101.59M | $4.27 | — |
News headlines (Yahoo Finance, 1h cache)
Pelthos Therapeutics to Participate in 2026 Jefferies Global Healthcare Conference
2026-05-28 21:00 · Yahoo
Pelthos Therapeutics Inc. Q1 2026 Earnings Call Summary
2026-05-15 12:30 · Yahoo
Pelthos Therapeutics Inc (PTHS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
2026-05-14 23:01 · Yahoo
Pelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates
2026-05-14 12:20 · Yahoo
Pelthos Therapeutics Announces First Quarter 2026 Financial Results
2026-05-14 11:00 · Yahoo
Pelthos Therapeutics to Report First Quarter 2026 Financial Results on May 14, 2026
2026-05-01 12:30 · Yahoo
Pelthos Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium
2026-04-14 12:30 · Yahoo
Pelthos Therapeutics Announces CFO Transition
2026-04-10 21:00 · Yahoo
Pelthos Therapeutics Announces First Patient Dosed in Phase 1b/2a Clinical Trial of CT2000 in Eye Pain
2026-03-31 12:30 · Yahoo
Pelthos Therapeutics Maps Public-Market Path, ZELSUVMI Surge, Adds Xepi and Xeglyze in Roth Interview
2026-03-29 08:04 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-06-15 17:25:26 | 2026-06-11 | Davis Todd C | Dir | P - Purchase | 27.82 | 35948 | 999983 |